All In Biotech

Drug Trial Radar · NCT00958776

A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza

A Phase 3, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Serious Influenza

Last checked: Nov 20, 2026Latest source record: Feb 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 405 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

405

Actual

Start

Nov 2009

Primary completion

Nov 2012

Study completion Oct 2013

Sponsor

Lead sponsor
BioCryst PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Department of Health and Human Services
First posted
Aug 13, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3, multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of peramivir administered intravenously in addition to standard of care compared to standard of care alone in adults and adolescents who are hospitalized due to serious influenza.

Conditions

  • Cough
  • Sore Throat
  • Nasal Congestion
  • Headache
  • Fever
  • Seasonal Influenza

Interventions

  • Peramivir+SOCDrug

    * Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care. * Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.

  • Placebo+SOCDrug

    Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Clinical Resolution (Kaplan-Meier Estimate)Time frame: 10 days

Locations

196 sites in 23 countries. Site status is shown where the registry gives one.

  • Site not named

    La Mesa, California

  • Site not named

    Long Beach, California

  • Site not named

    Modesto, California

  • Site not named

    Oceanside, California

  • Pulmonary Consultants PC Physicians Medical Group, Inc.

    Orange, California

  • Site not named

    Orange, California

  • UC Davis Medical Center

    Sacramento, California

  • Sharp Chula Vista Medical Center

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    Denver, Colorado

  • Drogue Medical, LLC

    Wheat Ridge, Colorado

  • Washington Hospital Center CAR

    Washington D.C., District of Columbia

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    West Palm Beach, Florida

  • Florida Hospital

    Winter Park, Florida

  • Site not named

    Columbus, Georgia

  • DeKalb Medical Center

    Decatur, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Honolulu, Hawaii

  • Medical Arts Associates, Ltd.

    Moline, Illinois

  • Site not named

    Springfield, Illinois

  • Site not named

    South Bend, Indiana

  • Kentucky Lung Clinic

    Hazard, Kentucky

  • Site not named

    Natchitoches, Louisiana

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Annapolis, Maryland

  • Site not named

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Wayne State University - Hutzel Hospital

    Detroit, Michigan

  • Wayne State University, Department of Emergency Medicine

    Detroit, Michigan

  • Site not named

    Detroit, Michigan

  • William Beaumont Hospital

    Royal Oak, Michigan

  • William Beaumont Hospital

    Troy, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Las Vegas, Nevada

  • Site not named

    New Brunswick, New Jersey

Showing 40 of 196 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.